Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

The restricted mean survival time (RMST) analysis technique was introduced in health care research about 25 years ago and since then has become widely used in economics, engineering, business and ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Innovative statistical method helps determine ideal threshold times in restricted mean survival time analyses.

We recently published a list of 10 Best Stocks to Invest in for Long Term. In this article, we are going to take a look at ...

Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said ...

(Reuters) -Amgen on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

ProQR Therapeutics N.V.’s PRQR share price has dipped by 5.52%, which has investors questioning if this is right time to buy.

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...